Everest Organics Ltd. (EVERESTO) Share Price Rises 10.47% as Micro Cap Stock Clears Price Rise Threshold

Everest Organics Ltd. Share Price Today rose to Rs 317, up 10.47%, taking market capitalisation to Rs 286.19 crore in a notable BSE move.

Everest Organics Ltd. Share Price moved to Rs 317 on 18 August 2026, up Rs 30.05 or 10.47% from the previous close of Rs 286.95, lifting the company’s market capitalisation to Rs 286.19 crore. In Stock Market Today terms, that made Everest Organics Ltd. one of the notable Stocks in News from the Healthcare space, especially within Pharmaceuticals & Drugs, where investors often track both price action and valuation shifts together.

The supplied data confirms a same-day price rise that qualified under the stock’s Micro Cap category. That is the event here: a verified share price gain large enough to clear its category threshold. The data establishes the move, the trading range and the valuation context, but it does not establish a company-specific catalyst behind today’s rise. For readers searching Everest Organics Ltd. Share Price Today, Everest Organics Ltd. Stock News, or Why Is Everest Organics Ltd. Rising Today, the most reliable takeaway is that the stock recorded a strong single-session move on BSE with a sharp percentage gain and a fresh burst of market attention.

Within the first hours of this Everest Organics Ltd. Share Price Update, the key metrics to monitor are straightforward: price at Rs 317, gain of 10.47%, turnover of Rs 0.30 crore, total volume of 9,365 shares on BSE, market cap of Rs 286.19 crore, P/E of 54.46, P/B of 3.55, ROE of 33.96 and ROCE of 33.76. Univest notes that investors following Everest Organics Ltd. Share Price generally need to weigh the strength of today’s move against valuation, profitability and industry benchmarks rather than price alone.

Everest Organics Ltd. (EVERESTO) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 317
Previous Close	Rs 286.95
Today's Change	+Rs 30.05 (+10.47%)
Day Open	Rs 294.9
Day High	Rs 319.9
Day Low	Rs 250
Current Volume (BSE)	9,365
BSE Traded Volume	9,365
Combined NSE + BSE Volume	9,365
Turnover	Rs 0.3 crore
Market Capitalisation	Rs 286.19 crore
Market Cap Category	Micro Cap

Everest Organics Ltd. (EVERESTO) traded at Rs 317. versus the previous close of Rs 286.95, a rise of 10.47%. The stock opened at Rs 294.9, reached Rs 319.9, touched Rs 250. Reported volume was 9,365.

Everest Organics Ltd. (EVERESTO) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 286.19 crore
P/E Ratio	54.46x
P/B Ratio	3.55x
ROE	33.96%
ROCE	33.76%
EPS	Rs 5.27
Dividend Yield	0%

Everest Organics Ltd. was valued at a P/E ratio of 54.46x, a P/B ratio of 3.55x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 33.96% and ROCE of 33.76%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 5.27, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Everest Organics Ltd. Fundamental Analysis starts with size and valuation. The company’s market capitalisation stands at Rs 286.19 crore, placing it firmly in the micro-cap bracket. Market capitalisation indicates company size rather than business quality, so investors tracking Everest Organics Ltd. Share Price should pair that figure with valuation and return ratios. On that score, the supplied P/E ratio is 54.46 and the P/B ratio is 3.55.

Those numbers indicate that the market is assigning a valuation multiple well above some healthcare peers, although not uniformly above the full industry range. The more supportive part of the fundamental picture is profitability. Return on equity is 33.96 and return on capital employed is 33.76, both of which are strong on a standalone basis. In practical terms, ROE measures return generated on shareholder equity, while ROCE measures returns on capital employed across the business. Both metrics suggest Everest Organics Ltd. has been generating robust returns relative to the capital base represented in the supplied data.

The earnings context also matters. EPS is 5.27, which means the earnings attributable to each share are Rs 5.27. With Everest Organics Ltd. Share Price at Rs 317, that EPS links directly to the supplied P/E of 54.46, reinforcing that investors are paying a premium multiple relative to current earnings. Dividend yield is 0, which means the current data does not show a cash payout yield supporting the stock at this price. For income-focused readers of Everest Organics Ltd. Stock News, that places greater emphasis on business profitability and valuation rather than yield.

There is no need to convert today’s price rise into a recommendation. Instead, the fundamental question is narrower and factual: are the supplied metrics good enough to keep the stock on investors’ radar? Univest would say the answer is yes in terms of profitability and market interest, but Everest Organics Ltd. Share Price also carries a valuation multiple that deserves close comparison with its industry benchmark and listed peers. That is where this Everest Organics Ltd. Stock Analysis becomes more useful than price action alone.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	54.46x
Benchmark Median P/E	26.24x
Benchmark Average P/E	39.98x
Benchmark P/E Range	2.96x to 359.13x
Company P/B Ratio	3.55x
Benchmark Median P/B	1.82x
Company ROE	33.96%
Benchmark Median ROE	10.49%
Company ROCE	33.76%
Benchmark Median ROCE	12.97%
Company Market Capitalisation	Rs 286.19 crore
Benchmark Median Market Cap	Rs 142.37 crore

Everest Organics Ltd. (EVERESTO) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Everest Organics Ltd. (EVERESTO) has a P/E ratio of 54.46x, which is above the benchmark median of 26.24x, a difference of +107.55%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Everest Organics Ltd. (EVERESTO) has a ROE of 33.96%, which is above the benchmark median of 10.49%, a difference of +223.74%. Everest Organics Ltd. (EVERESTO) has a ROCE of 33.76%, which is above the benchmark median of 12.97%, a difference of +160.29%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Everest Organics Ltd. Share Price is moving within the Healthcare sector and the Pharmaceuticals & Drugs industry. Against the supplied same-industry benchmark of 136 companies, the stock shows a mix of premium valuation and stronger-than-benchmark profitability, making sector context essential to interpreting today’s rise.

The sector snapshot gives a useful frame for Everest Organics Ltd. Share Price Today. In the same industry benchmark covering 136 companies, the company’s P/E ratio of 54.46 stands above the median P/E of 26.24 and above the average P/E of 39.98. The broader industry P/E range runs from 2.96 to 359.13 across 105 companies with available P/E data, so Everest Organics is above the centre of the pack but still within a wide valuation spread common in Pharmaceuticals & Drugs.

The P/B ratio tells a similar story. Everest Organics has a P/B of 3.55 versus an industry median of 1.82 and average of 2.49 across 135 companies, with the full range running from -11.02 to 16.76. That places the stock above benchmark central values on price-to-book as well. On valuation alone, Everest Organics Ltd. Share Price does not screen as cheap relative to the industry benchmark.

Profitability is where the comparison turns more favourable. The company’s ROE of 33.96 is well above the industry median of 10.49 and average of 8.10. Its ROCE of 33.76 is also far above the benchmark median of 12.97 and average of 15.53. Market capitalisation at Rs 286.19 crore sits above the industry median of Rs 142.37 crore but below the average of Rs 492.43 crore, within a wide range of Rs 6.06 crore to Rs 2,985.15 crore.

For readers following Everest Organics Ltd. News Today, this sector view matters because it shows why the stock can attract attention even without a verified company-specific trigger. Univest sees a clear pattern in the numbers: Everest Organics Ltd. Share Price is backed by return ratios that are stronger than benchmark norms, but it is also valued above industry medians, which makes both the price rise and the underlying multiples worth monitoring.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,985.15	170.32	0.42	-2.89	-0.26
Beta Drugs Ltd.	BETA	2,827.67	65.02	10.29	18.65	22.17
Hikal Ltd.	HIKAL	2,686.72	0	2.2	15.22	16.15
Ind-Swift Laboratories Ltd.	INDSWFTLAB	2,645.37	47.53	1.82	-0.78	8.31
Fredun Pharmaceuticals Ltd.	FREDUN	2,559.68	54.85	8.19	11.42	13.15

Everest Organics Ltd. (EVERESTO) has a P/E ratio of 54.46x compared with the displayed peer median of 54.85x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 33.96% compares with a peer median of 11.42% across the companies shown in the table. ROCE stood at 33.76% versus the displayed peer median of 13.15%, providing a capital-efficiency comparison. Everest Organics Ltd. (EVERESTO) has a market capitalisation of Rs 286.19 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Everest Organics Ltd. Share Price looks different depending on which peer metric is used. Compared with the listed Pharmaceuticals & Drugs names in the supplied peer set, the company is much smaller by market capitalisation but compares better on profitability than several larger peers, while its valuation sits near the middle of selected high-multiple names.

Market-cap scale is the biggest contrast. Everest Organics stands at Rs 286.19 crore, far below Dishman Carbogen Amcis at Rs 2,985.15 crore, Beta Drugs at Rs 2,827.67 crore, Hikal at Rs 2,686.72 crore, Ind-Swift Laboratories at Rs 2,645.37 crore and Fredun Pharmaceuticals at Rs 2,559.68 crore. Even the smallest market cap among the named peer examples here, NGL Fine-Chem, is Rs 2,139.20 crore, several times larger.

Valuation is more mixed. Everest Organics has a P/E of 54.46, which is lower than Dishman Carbogen Amcis at 170.32, Beta Drugs at 65.02 and Sai Parenteral’s at 170.53, but slightly above Fredun Pharmaceuticals at 54.85 only by a narrow margin in relative neighbourhood and above Ind-Swift Laboratories at 47.53, NGL Fine-Chem at 31.64 and Venus Remedies at 20.48. The company’s P/B of 3.55 is above Hikal’s 2.20, Ind-Swift’s 1.82, Solara’s 1.93 and Dishman’s 0.42, but below Beta Drugs at 10.29, Fredun at 8.19 and NGL Fine-Chem at 5.21.

Profitability stands out more positively. Everest Organics reports ROE of 33.96, ahead of Beta Drugs at 18.65, Hikal at 15.22, Fredun at 11.42, Venus Remedies at 9.85 and NGL Fine-Chem at 27.90. ROCE at 33.76 is also stronger than Beta Drugs at 22.17, Hikal at 16.15, Fredun at 13.15, Sai Parenteral’s at 12.97 and Venus Remedies at 7.89, while broadly comparable with NGL Fine-Chem’s 33.91. That peer mix helps explain why Everest Organics Ltd. Share Price can remain in focus despite its small size.

Why Investors Are Watching Everest Organics Ltd.

Everest Organics Ltd. Share Price is in focus because today’s move was large enough to clear the stock’s Micro Cap qualifying bar and place it among the stronger percentage movers in the market update. The stock also combines a premium valuation profile with profitability metrics that compare favourably against industry medians and several larger peers. For investors scanning Top Gainers Today, that is usually enough to justify deeper monitoring even when the supplied data does not identify a specific catalyst.

• Verified price action: The stock rose 10.47% to Rs 317 from Rs 286.95.
• Intraday range: It traded between Rs 250 and Rs 319.90, showing wide price action.
• Market cap context: Everest Organics remains a Micro Cap company at Rs 286.19 crore.
• Valuation: P/E of 54.46 and P/B of 3.55 are above industry median levels.
• Profitability: ROE of 33.96 and ROCE of 33.76 are both well above benchmark medians.
• Sector position: The company operates in Healthcare, within Pharmaceuticals & Drugs.

What should investors monitor next? The immediate checklist includes whether Everest Organics Ltd. Share Price holds near the upper end of today’s range, whether turnover expands beyond Rs 0.30 crore in follow-up sessions, and whether the premium valuation continues to be supported by profitability metrics relative to peers. Univest also suggests tracking how this Everest Organics Ltd. Share Price Rise fits into broader Market News and sector-relative performance rather than looking at a single day in isolation.

About Everest Organics Ltd.

Everest Organics Ltd. operates in the Healthcare sector and is classified under the Pharmaceuticals & Drugs industry. That industry context matters because Everest Organics Ltd. Share Price is being assessed alongside a broad set of 136 same-industry companies, ranging from micro-cap names to businesses with market capitalisations above Rs 2,900 crore.

Based on the verified company context supplied here, Everest Organics should be understood first as a listed pharmaceuticals player rather than through any unverified business claims. For investors reading Everest Organics Ltd. Company News or Everest Organics Ltd. Latest News, the core business lens available from the data is its position inside Pharmaceuticals & Drugs, where valuation multiples and return ratios often vary widely from one listed company to another.

The benchmark set includes companies such as Dishman Carbogen Amcis, Beta Drugs, Hikal, Ind-Swift Laboratories, Fredun Pharmaceuticals, Sai Parenteral’s, Panacea Biotec, Venus Remedies and NGL Fine-Chem. Within that listed context, Everest Organics Ltd. Share Price reflects a smaller company by market capitalisation, but one whose supplied ROE and ROCE are comparatively strong. That combination makes the stock relevant for readers interested in both micro-cap Healthcare names and broader Indian Stock Market trends in pharmaceuticals.

For practical purposes, the company’s listed identity in this article is anchored to symbol EVERESTO on BSE, current market cap of Rs 286.19 crore and its placement within Healthcare and Pharmaceuticals & Drugs. Univest uses that verified framework to keep the Everest Organics Ltd. Stock Analysis factual and focused.

Track Everest Organics Ltd. Share Price on Univest

Use Everest Organics Ltd. (EVERESTO) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors following Everest Organics Ltd. Share Price can use Univest to track live share price moves, 52-week levels, valuation ratios, profitability indicators and broader stock analysis in one place. For a stock like Everest Organics, where today’s percentage gain is large but company size remains in the micro-cap range, a structured dashboard helps put daily moves in context.

On Univest, users can monitor Everest Organics Ltd. Share Price Today alongside metrics such as market capitalisation, P/E ratio, P/B ratio, ROE, ROCE, EPS, dividend yield and peer comparison. The platform also helps readers follow Everest Organics Ltd. Stock News, sector trends in Healthcare and Pharmaceuticals & Drugs, and the broader market update without relying only on headline price moves.

Frequently Asked Questions

Why did Everest Organics Ltd. Share Price rise today?

Ans. Everest Organics Ltd. Share Price rose because the supplied data confirms a 10.47% same-day gain to Rs 317 from Rs 286.95. The move cleared the stock’s Micro Cap qualifying bar, although no company-specific catalyst is established in the verified data.

What was Everest Organics Ltd. Share Price Today?

Ans. Everest Organics Ltd. Share Price Today was Rs 317 at the time of the update. That was up Rs 30.05 from the previous close of Rs 286.95, making it one of the sharper percentage gainers in today’s BSE trade.

How much did Everest Organics Ltd. gain in today’s session?

Ans. The stock gained Rs 30.05 in absolute terms and 10.47% in percentage terms. For readers tracking Everest Organics Ltd. Stock News, that was the key event, supported by a move from Rs 286.95 to Rs 317.

What was the intraday range for Everest Organics Ltd. shares?

Ans. Everest Organics Ltd. traded between an intraday low of Rs 250 and a high of Rs 319.90. That wide band shows notable volatility, but the stock still ended the update much closer to the day’s high than the low.

On which exchange did the main volume appear for Everest Organics Ltd.?

Ans. The supplied trading volume came from BSE. BSE volume was 9,365 shares, which was also the total reported volume, while turnover for the session stood at Rs 0.30 crore in this Everest Organics Ltd. Share Price Update.

What is the market capitalisation of Everest Organics Ltd.?

Ans. Everest Organics Ltd. had a market capitalisation of Rs 286.19 crore in the supplied data. That places the company in the Micro Cap category, which is important because today’s price rise is assessed within that size bracket.

Is Everest Organics Ltd. expensive relative to its industry benchmark?

Ans. On the supplied figures, Everest Organics appears valued above industry central levels. Its P/E is 54.46 versus a benchmark median of 26.24 and average of 39.98, while its P/B of 3.55 is above the median 1.82.

How profitable is Everest Organics Ltd. compared with the industry benchmark?

Ans. The profitability ratios are strong relative to the benchmark. Everest Organics reports ROE of 33.96 and ROCE of 33.76, both well above the same-industry medians of 10.49 and 12.97, respectively, in Pharmaceuticals & Drugs.

What do EPS and dividend yield show for Everest Organics Ltd.?

Ans. The supplied EPS is 5.27, meaning earnings attributable to each share are Rs 5.27. Dividend yield is 0, so the current data does not show a cash yield component supporting Everest Organics Ltd. Share Price.

How does Everest Organics Ltd. compare with selected listed peers?

Ans. Everest Organics is smaller than peers such as Beta Drugs, Hikal and Fredun Pharmaceuticals by market cap, but its ROE of 33.96 and ROCE of 33.76 compare favourably with many of those larger Pharmaceuticals & Drugs companies.